The CorePlus pathology lab in Carolina Puerto Rico is the first in the Americas to detect prostate cancer using the AI-based software from Israel’s Ibex Medical Analytics (reported previously). The system is already in use in the UK and in France.
The synthetic cornea from Israel’s CorNeat is beginning human trials, as reported in July. This has become vital due to shortage of human corneas during Covid-19. CorNeat will soon begin trials of its EverPatch for Glaucoma surgery and is developing the eShunt to reduce eye pressure.
More details about the development of StreamO2 – the low-cost breathing machine for Covid-19 patients built by Israeli fizzy-drinks maker SodaStream (reported previously). StreamO2 was the idea of Hadassah ICU doctor Akiva Nachshon, and recently tested successfully at Hadassah Ein Kerem in Jerusalem.
Sheba Medical Center has launched its “Gulf” initiative with the first agreement between an Israeli hospital and an organization in the United Arab Emirates. Sheba will work with UAE’s APEX National Investment on key medical challenges from COVID-19 to the future of hospital care.
The Israeli government is to set up a new national laboratory at the Hebrew University of Jerusalem for the study of viruses. It will help Israel counter pathogens after the Covid-19 pandemic. It will have special air conditioning, advanced testing tools and high-level protective gear.
11 of the 12 trial patients treated with the IgG Covid-19 treatment from Israel’s Kamada (reported previously) have now recovered and been discharged from hospital.
Doctors at Israel’s Sheba Medical Center are to test the use of low-dosage radiation on 30 severe Covid-19 patients. It is expected to reduce the inflammatory cells that invade the lungs of coronavirus patients and prevent them from oxygenating the blood.
Barts Health, one of the largest providers to the UK’s National Health Service, has selected the ColonFlag software from Israel’s Medial EarlySign (reported previously) to identify members at high risk for developing colon cancer – the UK’s 4th most common cancer.
Israel’s Pluristem (reported previously) has launched an FDA-cleared Covid-19 expanded access program. It enables Pluristem to use its PLX-PAD cells to treat up to 100 more infected patients outside its current trials in the USA and Europe and compassionate use in Israel.
Israel’s Elicio Therapeutics has published the results of a pre-clinical study of its ELI-005 protein subunit vaccine for Covid-19. It extended the life of coronavirus antibodies and may resolve the problem whereby patients who recover from the virus can be re-infected if later exposed to it.